Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.99-2.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Zentalis aims to finish DENALI Part 2 enrollment by end of 2026. It is advancing the ASPENOVA Phase 3 trial for azenosertib. The company chose the best dose for azenosertib in DENALI. These steps could lead to drug approval and future sales.
Zentalis is still losing money and has no revenue yet. Clinical trials face delays or failures. The stock price dropped 28% from its high. These risks could hurt the company’s value.
The stock trades about 18% below our fair value near $5. The market expects negative earnings growth over 3 to 5 years. Our view is cautious given ongoing losses and trial risks.
Breaks if: Trial progress stalls or is delayed significantly in 2026
Breaks if: Dose optimization is reversed or questioned in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. ZNTL is currently loss-making and has shown weak recent financial performance, which adds to the uncertainty in its long-term thesis.
The market appears to have priced in a low confidence level regarding ZNTL's future performance, as it is considered cheap compared to peers. However, expectations are fragile due to the company's recent earnings misses and elevated risk factors.
Fundamentals may continue to struggle in the near term, especially given the high probability of missing earnings expectations. Management is focused on completing key trials, but recent performance has not met industry standards.
The thesis hinges on the outcomes of ongoing clinical trials and the overall health of the healthcare sector. Positive developments from sector leaders could provide a lift, while any negative guidance or economic downturns could weigh heavily on ZNTL.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss is a concern. The company needs to maintain its financial runway into late 2027. This situation may challenge investor confidence.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Enrollment not completed by end of 2026
In the next 1 to 3 years, ZNTL's performance will likely depend on trial results and broader market conditions. Not investment advice.